Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for
the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.